Yizhuo Kelly Gao1, Markus Kuksis2, Badr Id Said3, Rania Chehade1,4, Alex Kiss5, William Tran3, Faisal Sickandar5, Arjun Sahgal3, Ellen Warner1,4, Hany Soliman3, Katarzyna J Jerzak1,4,5. 1. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 2. School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada. 3. Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 5. Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Breast cancer is the most common cancer among women worldwide and the second leading cause of brain metastases (BrM). We assessed the treatment patterns and outcomes of women treated for breast cancer BrM at our institution in the modern era of stereotactic radiosurgery (SRS). MATERIALS AND METHODS: We conducted a retrospective analysis of women (≥18 years of age) with metastatic breast cancer who were treated with surgery, whole brain radiotherapy (WBRT), or SRS to the brain at the Sunnybrook Odette Cancer Centre, Toronto, Canada, between 2008 and 2018. Patients with a history of other malignancies and those with an uncertain date of diagnosis of BrM were excluded. Descriptive statistics were generated and survival analyses were performed with subgroup analyses by breast cancer subtype. RESULTS: Among 683 eligible patients, 153 (22.4%) had triple-negative breast cancer, 188 (27.5%) had HER2+, 246 (36.0%) had hormone receptor (HR)+/HER2-, and 61 (13.3%) had breast cancer of an unknown subtype. The majority of patients received first-line WBRT (n = 459, 67.2%) or SRS (n = 126, 18.4%). The median brain-specific progression-free survival and median overall survival (OS) were 4.1 months (interquartile range [IQR] 1.0-9.6 months) and 5.1 months (IQR 2.0-11.7 months) in the overall patent population, respectively. Age >60 years, presence of neurological symptoms at BrM diagnosis, first-line WBRT, and HER2- subtype were independently prognostic for shorter OS. CONCLUSION: Despite the use of SRS, outcomes among patients with breast cancer BrM remain poor. Strategies for early detection of BrM and central nervous system-active systemic therapies warrant further investigation. IMPLICATIONS FOR PRACTICE: Although triple-negative breast cancer and HER2+ breast cancer have a predilection for metastasis to the central nervous system (CNS), patients with hormone receptor-positive/HER2- breast cancer represent a high proportion of patients with breast cancer brain metastases (BrM). Hence, clinical trials should include patients with BrM and evaluate CNS-specific activity of novel systemic therapies when feasible, irrespective of breast cancer subtype. In addition, given that symptomatic BrM are associated with shorter survival, this study suggests that screening programs for the early detection and treatment of breast cancer BrM warrant further investigation in an era of minimally toxic stereotactic radiosurgery.
BACKGROUND: Breast cancer is the most common cancer among women worldwide and the second leading cause of brain metastases (BrM). We assessed the treatment patterns and outcomes of women treated for breast cancer BrM at our institution in the modern era of stereotactic radiosurgery (SRS). MATERIALS AND METHODS: We conducted a retrospective analysis of women (≥18 years of age) with metastatic breast cancer who were treated with surgery, whole brain radiotherapy (WBRT), or SRS to the brain at the Sunnybrook Odette Cancer Centre, Toronto, Canada, between 2008 and 2018. Patients with a history of other malignancies and those with an uncertain date of diagnosis of BrM were excluded. Descriptive statistics were generated and survival analyses were performed with subgroup analyses by breast cancer subtype. RESULTS: Among 683 eligible patients, 153 (22.4%) had triple-negative breast cancer, 188 (27.5%) had HER2+, 246 (36.0%) had hormone receptor (HR)+/HER2-, and 61 (13.3%) had breast cancer of an unknown subtype. The majority of patients received first-line WBRT (n = 459, 67.2%) or SRS (n = 126, 18.4%). The median brain-specific progression-free survival and median overall survival (OS) were 4.1 months (interquartile range [IQR] 1.0-9.6 months) and 5.1 months (IQR 2.0-11.7 months) in the overall patent population, respectively. Age >60 years, presence of neurological symptoms at BrM diagnosis, first-line WBRT, and HER2- subtype were independently prognostic for shorter OS. CONCLUSION: Despite the use of SRS, outcomes among patients with breast cancer BrM remain poor. Strategies for early detection of BrM and central nervous system-active systemic therapies warrant further investigation. IMPLICATIONS FOR PRACTICE: Although triple-negative breast cancer and HER2+ breast cancer have a predilection for metastasis to the central nervous system (CNS), patients with hormone receptor-positive/HER2- breast cancer represent a high proportion of patients with breast cancer brain metastases (BrM). Hence, clinical trials should include patients with BrM and evaluate CNS-specific activity of novel systemic therapies when feasible, irrespective of breast cancer subtype. In addition, given that symptomatic BrM are associated with shorter survival, this study suggests that screening programs for the early detection and treatment of breast cancer BrM warrant further investigation in an era of minimally toxic stereotactic radiosurgery.
Authors: I Witzel; E Laakmann; R Weide; T Neunhöffer; T-J Park-Simon; M Schmidt; P A Fasching; T Hesse; A Polasik; S Mohrmann; F Würschmidt; C Schem; C Bechtner; R Würstlein; T Fehm; V Möbus; N Burchardi; S Loibl; V Müller Journal: Eur J Cancer Date: 2018-08-09 Impact factor: 9.162
Authors: Sung Sook Lee; Jin-Hee Ahn; Min Kyoung Kim; Sun Jin Sym; Gyungyub Gong; Seung Do Ahn; Sung-Bae Kim; Woo Kun Kim Journal: Breast Cancer Res Treat Date: 2007-11-08 Impact factor: 4.872
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: J Clin Oncol Date: 2020-09-15 Impact factor: 44.544
Authors: Rashmi K Murthy; Sherene Loi; Alicia Okines; Elisavet Paplomata; Erika Hamilton; Sara A Hurvitz; Nancy U Lin; Virginia Borges; Vandana Abramson; Carey Anders; Philippe L Bedard; Mafalda Oliveira; Erik Jakobsen; Thomas Bachelot; Shlomit S Shachar; Volkmar Müller; Sofia Braga; Francois P Duhoux; Richard Greil; David Cameron; Lisa A Carey; Giuseppe Curigliano; Karen Gelmon; Gabriel Hortobagyi; Ian Krop; Sibylle Loibl; Mark Pegram; Dennis Slamon; M Corinna Palanca-Wessels; Luke Walker; Wentao Feng; Eric P Winer Journal: N Engl J Med Date: 2019-12-11 Impact factor: 91.245
Authors: Christian Maurer; Lorraine Tulpin; Michel Moreau; Cristina Dumitrescu; Evandro de Azambuja; Marianne Paesmans; Jean-Marie Nogaret; Martine J Piccart; Ahmad Awada Journal: ESMO Open Date: 2018-10-24
Authors: Eric D Routh; Amanda E D Van Swearingen; Maria J Sambade; Steven Vensko; Marni B McClure; Mark G Woodcock; Shengjie Chai; Luz A Cuaboy; Amy Wheless; Amy Garrett; Lisa A Carey; Alan P Hoyle; Joel S Parker; Benjamin G Vincent; Carey K Anders Journal: Front Oncol Date: 2022-07-27 Impact factor: 5.738
Authors: Xin Ye Wang; Michael N Rosen; Rania Chehade; Arjun Sahgal; Sunit Das; Ellen Warner; Refik Saskin; Bo Zhang; Hany Soliman; Kelvin K W Chan; Katarzyna J Jerzak Journal: JAMA Netw Open Date: 2022-08-01